Evidence of delayed progression is the primary mechanism for demonstrating therapeutic e cacy in clinical trials in Alzheimer's disease. In the major trials of therapeutic treatment of AD, to date, measures based on clinical judgement and cognitive performance, instead of mortality, have been used a
Multicenter trial of naloxone in alzheimer's disease
โ Scribed by Dr. V. W. Henderson; E. Roberts; C. Wimer; E. L. Bardolph; H. C. Chui; A. R. Damasio; P. J. Eslinger; M. F. Folstein; L. S. Schneider; E. L. Teng; L. E. Tune; L. P. Weiner; P. J. Whitehouse
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 312 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The presenilins (PS-1 and PS-2) are 2 members of a novel family of genes encoding integral membrane proteins recently implicated in Alzheimer's disease (AD) pathology. To date, 43 mutations have been identified in PS-1 and 2 in PS-2 that lead to familial presenile AD (onset before age 65 years). The
Shropshire highlighted a lack of action following the detection of abnormal lithium levels (Myers and Hallworth, 1996). There have also been a number of reports regarding ways in which monitoring could be improved. Dedicated lithium clinics have been shown to provide a better standard of monitoring